What is the recommended outpatient pharmacologic treatment plan for ADHD, including first‑line stimulant options, dosing, monitoring, and alternative medications?

Outpatient ADHD Pharmacologic Treatment

Stimulant medications—specifically methylphenidate (MPH) or amphetamine (AMP)—are first-line treatment for ADHD, with methylphenidate 5 mg twice daily (after breakfast and lunch) or amphetamine/dextroamphetamine 2.5 mg once daily as starting doses, titrated weekly based on symptom response. 1

First-Line Treatment: Stimulants

Initial Medication Selection

Choose between methylphenidate or amphetamine based on:

• Methylphenidate preferred initially due to less impact on appetite and sleep compared to amphetamines 1
• Either medication is acceptable as first choice depending on clinician and patient preference 1
• Avoid pemoline due to risk of hepatic failure 1

Starting Doses and Titration

Children and Adolescents:

• Methylphenidate: 5 mg twice daily (morning after breakfast, noon after lunch)
• Amphetamine/Dextroamphetamine: 2.5 mg once daily in early morning, add noon dose if needed 1
• Titrate weekly in 5 mg (MPH) or 2.5 mg (AMP) increments 1
• Maximum doses: MPH 60 mg/day, AMP 40 mg/day for most patients 1, 2

Adults:

• Start with same doses as adolescents (5 mg MPH or 2.5 mg AMP)
• Titrate in 5-10 mg intervals weekly
• May require higher total daily doses (up to 1.0 mg/kg MPH or 0.9 mg/kg AMP) to cover longer day 1

Formulation Selection

Long-acting formulations are preferred due to:

• Better medication adherence
• Lower risk of rebound effects
• Reduced diversion potential 3

Short-acting formulations allow more flexibility for titration and dosing frequency 3

Available extended-release options include OROS-MPH, lisdexamfetamine, dermal methylphenidate, and various controlled-release formulations 4, 2

Pre-Treatment Requirements

Baseline Assessment

Before initiating stimulants, obtain 1:

• Blood pressure and pulse
• Height and weight
• Physical examination to identify hypertension or cardiac arrhythmias
• Documentation of prior treatments (medications, doses, duration, response, side effects)
• Assessment for substance abuse history (especially in adolescents) 4

Contraindications

Absolute contraindications 1:

• Previous stimulant sensitivity
• Glaucoma
• Symptomatic cardiovascular disease
• Hyperthyroidism
• Hypertension
• Active psychotic disorder
• Concurrent MAO inhibitor use
• History of stimulant abuse (unless controlled setting)

Relative contraindications (FDA package insert warnings, though recent literature suggests may not worsen):

• Motor tics or Tourette's disorder
• Marked anxiety
• Seizure disorder (initiate MPH after seizures controlled with anticonvulsants) 1

Monitoring Schedule

Children:

• Vital signs checked annually during routine physical examination 1

Adults:

• Blood pressure and pulse quarterly by treating or primary care physician 1

All patients:

• Monitor height, weight, appetite, sleep, cardiovascular symptoms 3
• Assess for mood disturbances, anxiety, psychotic symptoms 5

Second-Line Treatment: Alternative Stimulant

If first stimulant fails or causes intolerable side effects, switch to the alternative stimulant class (if started on methylphenidate, switch to amphetamine or vice versa) 1

• Approximately 70% respond to either MPH or AMP alone
• Nearly 90% respond if both stimulant classes are tried 1, 6

Third-Line Treatment: Non-Stimulants

Consider non-stimulants when 3:

• Inadequate response to both stimulant classes
• Intolerable stimulant side effects
• Substance abuse risk/active substance use
• Patient/family preference
• Comorbid tic disorder, anxiety, or sleep problems

Atomoxetine

• Starting dose: Weight-based titration to maximum 1.4 mg/kg/day or 100 mg/day (whichever lower) 3
• Takes 6-12 weeks for full effect 3
• Monitor for suicidality especially first few months or dose changes 3
• Common side effects: decreased appetite, nausea, vomiting, fatigue, abdominal pain 3

Alpha-2 Agonists (Guanfacine ER, Clonidine ER)

• Takes 2-4 weeks for effect 3
• Useful for comorbid sleep problems, aggression, tics 3, 7
• Common side effects: somnolence, fatigue, hypotension, bradycardia 3
• Must taper off gradually to avoid rebound hypertension 8

Special Populations

Preschool Children (Ages 4-5)

• Methylphenidate is recommended first-line if behavioral therapy inadequate 4, 8
• Use only for moderate-to-severe ADHD with dysfunction in multiple settings 8
• Start lower doses, increase in smaller increments (slower metabolism) 4
• Note: Use remains off-label despite moderate evidence for safety/efficacy 8

Adolescents

• Screen for substance abuse before initiating treatment 4
• Consider formulations with lower diversion potential: lisdexamfetamine, dermal MPH, OROS-MPH 4
• Provide medication coverage for driving (longer-acting or late-afternoon short-acting) 4

Adults

• Same stimulant first-line approach as children/adolescents 5, 9
• May require more frequent dosing to cover longer day 1
• Integrate pharmacotherapy with psychological therapies and allied health support 5

Adjunctive Therapy

Only extended-release guanfacine and extended-release clonidine have FDA approval for adjunctive use with stimulants 8

Limited evidence supports atomoxetine as adjunctive therapy with stimulants 8

Common Pitfalls to Avoid

• Underdosing: Community treatment often uses lower doses than optimal; systematic titration through full dose range yields better outcomes 6
• Premature discontinuation: If no response at low dose, continue titrating upward before switching medications
• Inadequate monitoring: Quarterly vital signs in adults often missed
• Ignoring substance abuse screening in adolescents before prescribing
• Not considering long-acting formulations which improve adherence and reduce diversion risk